/stocks — the workspaceLOADING
Thermo Fisher sells lab instruments, reagents, and single-use consumables that pharma and biotech researchers reorder constantly. Its PPD unit runs clinical trials for drugmakers, and Patheon manufactures their drugs under contract.
THERMO FISHER SCIENTIFIC INC. (TMO) is a measuring & controlling devices, nec company. Piotroski F-Score 5/7. 16 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-07-22 from TMO's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
Led by Marc Casper · see pay & career →
EOD daily bars · delayed, not real-time · data: DatabentoCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
A plain-English read on TMO plus an auto-SWOT — built from TMO's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate TMO using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
| GMO (Jeremy Grantham) | $1.23B | 3.1% of portfolio |
| Generation Investment Management (Al Gore) | $380.2M | 3.4% of portfolio |
| Dwight EvansU.S. Representative · PA-02 | SELL | $1,001 - $15,000 | filed 2026-05-15 |
Projected from TMO's own SEC 8-K filing history — the year-over-year reporting pattern (~50% land the exact day, ~90% within a week). No analyst estimates, no scraped calendars, nothing invented. It upgrades to a confirmed date + time the moment TMO files its announcement.
TMO's earnings reaction has been evenly split — 4 up, 4 down across its last 8 reports.
Earnings reactions have been moderate.
The average is inflated by its most volatile prints (+11.1% and -8.6%).
A more typical earnings reaction has been approximately ±5.1%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-04-23 | -8.6% |
| 2026-01-29 | -4.8% |
| 2025-10-22 | +2.5% |
| 2025-07-23 | +11.1% |
| 2025-04-23 | -1.9% |
| 2025-01-30 | +5.2% |
| 2024-10-23 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -4.9% |
| 2024-07-24 | +7.7% |
| Pettiti GianlucaPresident & COO | SELL | $185K | view → |
| Shafer Michael DExecutive Vice President | SELL | $803K | view → |
| CASPER MARC NChairman & CEO | SELL | $2.1M | view → |
| CASPER MARC NChairman & CEO | SELL | $5.1M | view → |